

CLNE0029: Clinical neuroscience of neurodegenerative diseases

[View Online](#)

[1]

C. Clarke, R. Howard, M. Rossor, and S. D. Shorvon, Eds., *Neurology: a Queen Square textbook*, Second edition. Chichester, West Sussex, UK: Wiley Blackwell, 2016 [Online]. Available: <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160>

[2]

R. A. McCarthy and E. K. Warrington, *Cognitive neuropsychology: a clinical introduction*. San Diego, California: Academic Press, Inc, 1990 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760

[3]

M. Rossor and J. H. Growdon, *The dementias 2*. [Place of publication not identified]: Butterworth Heinemann/Elsevier, 2007 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760

[4]

J. R. Hodges, *Cognitive assessment for clinicians*, 3 ed. [Oxford]: Oxford University Press, 2017 [Online]. Available: <http://dx.doi.org/10.1093/med/9780198749189.001.0001>

[5]

E. R. Kandel, J. H. Schwartz, T. M. Jessell, S. Siegelbaum, and A. J. Hudspeth, Eds.,

Principles of neural science, Fifth edition. New York: McGraw Hill Medical, 2013 [Online]. Available:
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760

[6]

M. Husain, Oxford textbook of cognitive neurology and dementia. [Oxford]: Oxford University Press, 2016 [Online]. Available:
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760

[7]

'Alzheimer's Facts and Figures Report | Alzheimer's Association'. [Online]. Available:
<https://www.alz.org/alzheimers-dementia/facts-figures>

[8]

D. J. Selkoe and J. Hardy, 'The amyloid hypothesis of Alzheimer's disease at 25 years', EMBO Molecular Medicine, vol. 8, no. 6, pp. 595–608, Jun. 2016, doi: 10.15252/emmm.201606210.

[9]

B. Dubois et al., 'Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria', The Lancet Neurology, vol. 13, no. 6, pp. 614–629, Jun. 2014, doi: 10.1016/S1474-4422(14)70090-0.

[10]

C. T. Loy, P. R. Schofield, A. M. Turner, and J. B. Kwok, 'Genetics of dementia', The Lancet, vol. 383, no. 9919, pp. 828–840, Mar. 2014, doi: 10.1016/S0140-6736(13)60630-3.

[11]

E. Karran and J. Hardy, 'Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?', New England Journal of Medicine, vol. 370, no. 4, pp. 377–378, Jan. 2014,

doi: 10.1056/NEJMe1313943.

[12]

K. A. Johnson, N. C. Fox, R. A. Sperling, and W. E. Klunk, 'Brain Imaging in Alzheimer Disease', *Cold Spring Harbor Perspectives in Medicine*, vol. 2, no. 4, pp. a006213–a006213, Apr. 2012, doi: 10.1101/cshperspect.a006213.

[13]

C. A. Ross et al., 'Huntington disease: natural history, biomarkers and prospects for therapeutics', *Nature Reviews Neurology*, vol. 10, no. 4, pp. 204–216, Apr. 2014, doi: 10.1038/nrneurol.2014.24.

[14]

G. P. Bates et al., 'Huntington disease', *Nature Reviews Disease Primers*, Apr. 2015, doi: 10.1038/nrdp.2015.5.

[15]

E. J. Wild and S. J. Tabrizi, 'Therapies targeting DNA and RNA in Huntington's disease', *The Lancet Neurology*, vol. 16, no. 10, pp. 837–847, Oct. 2017, doi: 10.1016/S1474-4422(17)30280-6.

[16]

J. B. Carroll, G. P. Bates, J. Steffan, C. Saft, and S. J. Tabrizi, 'Treating the whole body in Huntington's disease', *The Lancet Neurology*, vol. 14, no. 11, pp. 1135–1142, Nov. 2015, doi: 10.1016/S1474-4422(15)00177-5.

[17]

S. J. Tabrizi et al., 'Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis', *The Lancet Neurology*, vol. 10, no. 1, pp. 31–42, Jan. 2011, doi: 10.1016/S1474-4422(10)70276-3.

[18]

S. J. Tabrizi et al., 'Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data', *The Lancet Neurology*, vol. 11, no. 1, pp. 42–53, Jan. 2012, doi: 10.1016/S1474-4422(11)70263-0.

[19]

S. J. Tabrizi et al., 'Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data', *The Lancet Neurology*, vol. 12, no. 7, pp. 637–649, Jul. 2013, doi: 10.1016/S1474-4422(13)70088-7.

[20]

L. Jones, H. Houlden, and S. J. Tabrizi, 'DNA repair in the trinucleotide repeat disorders', *The Lancet Neurology*, vol. 16, no. 1, pp. 88–96, Jan. 2017, doi: 10.1016/S1474-4422(16)30350-7.

[21]

M. Rossor et al., 'Dementia and Cognitive Impairment', in *Neurology*, C. Clarke, R. Howard, M. Rossor, and S. Shorvon, Eds. Chichester, UK: John Wiley & Sons, Ltd, 2016, pp. 289–336 [Online]. Available: <http://doi.wiley.com/10.1002/9781118486160.ch8>

[22]

M. N. Rossor, N. C. Fox, C. J. Mummery, J. M. Schott, and J. D. Warren, 'The diagnosis of young-onset dementia', *The Lancet Neurology*, vol. 9, no. 8, pp. 793–806, Aug. 2010, doi: 10.1016/S1474-4422(10)70159-9.

[23]

J. M. Schott, N. C. Fox, and M. N. Rossor, 'Assessment and investigation of the cognitively impaired adult', in *Oxford Textbook of Cognitive Neurology and Dementia*, M. Husain and J. M. Schott, Eds. Oxford University Press, 2016, pp. 221–230 [Online]. Available: <http://oxfordmedicine.com/view/10.1093/med/9780199655946.001.0001/med-9780199655946-chapter-21>

[24]

A. J. E. Green, 'RT-QuIC: a new test for sporadic CJD', *Practical Neurology*, Oct. 2018, doi: 10.1136/practneurol-2018-001935.

[25]

J. Collinge, 'Mammalian prions and their wider relevance in neurodegenerative diseases', *Nature*, vol. 539, no. 7628, pp. 217–226, Nov. 2016, doi: 10.1038/nature20415.

[26]

S. Mead and P. Rudge, 'CJD mimics and chameleons', *Practical Neurology*, vol. 17, no. 2, pp. 113–121, Apr. 2017, doi: 10.1136/practneurol-2016-001571.

[27]

Z. Walker, K. L. Possin, B. F. Boeve, and D. Aarsland, 'Lewy body dementias', *The Lancet*, vol. 386, no. 10004, pp. 1683–1697, Oct. 2015, doi: 10.1016/S0140-6736(15)00462-6.

[28]

G. M. Halliday, J. L. Holton, T. Revesz, and D. W. Dickson, 'Neuropathology underlying clinical variability in patients with synucleinopathies', *Acta Neuropathologica*, vol. 122, no. 2, pp. 187–204, Aug. 2011, doi: 10.1007/s00401-011-0852-9.

[29]

R. A. Barker and C. H. Williams-Gray, 'Review: The spectrum of clinical features seen with alpha synuclein pathology', *Neuropathology and Applied Neurobiology*, vol. 42, no. 1, pp. 6–19, Feb. 2016, doi: 10.1111/nan.12303.

[30]

J. Bras et al., 'Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies', *Human Molecular Genetics*, vol. 23, no. 23, pp. 6139–6146, Dec. 2014, doi: 10.1093/hmg/ddu334.

[31]

I. G. McKeith et al., 'Diagnosis and management of dementia with Lewy bodies', *Neurology*, vol. 89, no. 1, pp. 88–100, Jul. 2017, doi: 10.1212/WNL.0000000000004058.

[32]

R. S. Weil, T. L. Lashley, J. Bras, A. E. Schrag, and J. M. Schott, 'Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies', *F1000Research*, vol. 6, Aug. 2017, doi: 10.12688/f1000research.11725.1.

[33]

I. O. C. Woollacott and J. D. Rohrer, 'The clinical spectrum of sporadic and familial forms of frontotemporal dementia', *Journal of Neurochemistry*, vol. 138, pp. 6–31, Aug. 2016, doi: 10.1111/jnc.13654.

[34]

E. Gordon, J. D. Rohrer, and N. C. Fox, 'Advances in neuroimaging in frontotemporal dementia', *Journal of Neurochemistry*, vol. 138, pp. 193–210, Aug. 2016, doi: 10.1111/jnc.13656.

[35]

R. M. Ahmed et al., 'Neuronal network disintegration: common pathways linking neurodegenerative diseases', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 87, no. 11, pp. 1234–1241, Nov. 2016, doi: 10.1136/jnnp-2014-308350.

[36]

P. D. Fletcher and J. D. Warren, 'Semantic Dementia: a specific network-opathy', *Journal of Molecular Neuroscience*, vol. 45, no. 3, pp. 629–636, Nov. 2011, doi: 10.1007/s12031-011-9586-3.

[37]

J. C. Goll et al., 'Non-verbal sound processing in the primary progressive aphasias', *Brain*,

vol. 133, no. 1, pp. 272–285, Jan. 2010, doi: 10.1093/brain/awp235.

[38]

J. C. Goll, G. R. Ridgway, S. J. Crutch, F. E. Theunissen, and J. D. Warren, 'Nonverbal sound processing in semantic dementia: A functional MRI study', *NeuroImage*, vol. 61, no. 1, pp. 170–180, May 2012, doi: 10.1016/j.neuroimage.2012.02.045.

[39]

M. L. Gorno-Tempini et al., 'Classification of primary progressive aphasia and its variants', *Neurology*, vol. 76, no. 11, pp. 1006–1014, Mar. 2011, doi: 10.1212/WNL.0b013e31821103e6.

[40]

M. Grossman, 'The non-fluent/agrammatic variant of primary progressive aphasia', *The Lancet Neurology*, vol. 11, no. 6, pp. 545–555, Jun. 2012, doi: 10.1016/S1474-4422(12)70099-6.

[41]

C. E. Leyton, J. R. Hodges, C. A. McLean, J. J. Kril, O. Piguet, and K. J. Ballard, 'Is the logopenic-variant of primary progressive aphasia a unitary disorder?', *Cortex*, vol. 67, pp. 122–133, Jun. 2015, doi: 10.1016/j.cortex.2015.03.011.

[42]

C. R. Marshall et al., 'Primary progressive aphasia: a clinical approach', *Journal of Neurology*, vol. 265, no. 6, pp. 1474–1490, Jun. 2018, doi: 10.1007/s00415-018-8762-6.

[43]

J. D. Rohrer, W. D. Knight, J. E. Warren, N. C. Fox, M. N. Rossor, and J. D. Warren, 'Word-finding difficulty: a clinical analysis of the progressive aphasia', *Brain*, vol. 131, no. 1, pp. 8–38, Dec. 2007, doi: 10.1093/brain/awm251.

[44]

J. D. Rohrer et al., 'Progressive logopenic/phonological aphasia: Erosion of the language network', *NeuroImage*, vol. 49, no. 1, pp. 984–993, Jan. 2010, doi: 10.1016/j.neuroimage.2009.08.002.

[45]

J. D. Rohrer, M. N. Rossor, and J. D. Warren, 'Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis', *Neurology*, vol. 75, no. 7, pp. 603–610, Aug. 2010, doi: 10.1212/WNL.0b013e3181ed9c6b.

[46]

J. D. Rohrer, D. Sauter, S. Scott, M. N. Rossor, and J. D. Warren, 'Receptive prosody in nonfluent primary progressive aphasia', *Cortex*, vol. 48, no. 3, pp. 308–316, Mar. 2012, doi: 10.1016/j.cortex.2010.09.004.

[47]

J. D. Warren, J. D. Rohrer, and M. N. Rossor, 'Frontotemporal dementia', *BMJ*, vol. 347, no. aug12 3, pp. f4827–f4827, Aug. 2013, doi: 10.1136/bmj.f4827.

[48]

D. S. Lynch et al., 'Clinical and genetic characterization of leukoencephalopathies in adults', *Brain*, vol. 140, no. 5, pp. 1204–1211, May 2017, doi: 10.1093/brain/awx045.

[49]

C. E. M. Hollak and R. Lachmann, Eds., *Inherited metabolic disease in adults: a clinical guide*. [New York]: Oxford University Press, 2016 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760

[50]

E. Devenney, S. Vucic, J. R. Hodges, and M. C. Kiernan, 'Motor neuron disease-frontotemporal dementia: a clinical continuum', *Expert Review of*

Neurotherapeutics, vol. 15, no. 5, pp. 509–522, May 2015, doi:
10.1586/14737175.2015.1034108.

[51]

M. J. Strong et al., 'Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 18, no. 3–4, pp. 153–174, Apr. 2017, doi:
10.1080/21678421.2016.1267768.

[52]

A. Iranzo et al., 'Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients', PLoS ONE, vol. 9, no. 2, Feb. 2014, doi:
10.1371/journal.pone.0089741.

[53]

S. A. Kielb, S. Ancoli-Israel, G. W. Rebok, and A. P. Spira, 'Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment', NeuroMolecular Medicine, vol. 14, no. 3, pp. 180–193, Sep. 2012, doi:
10.1007/s12017-012-8182-1.

[54]

B. A. Mander, J. R. Winer, W. J. Jagust, and M. P. Walker, 'Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?', Trends in Neurosciences, vol. 39, no. 8, pp. 552–566, Aug. 2016, doi:
10.1016/j.tins.2016.05.002.

[55]

S. J. McCarter, E. K. St. Louis, and B. F. Boeve, 'Sleep Disturbances in Frontotemporal Dementia', Current Neurology and Neuroscience Reports, vol. 16, no. 9, Sep. 2016, doi:
10.1007/s11910-016-0680-3.

[56]

S. Ooms and Y.-E. Ju, 'Treatment of Sleep Disorders in Dementia', Current Treatment

Options in Neurology, vol. 18, no. 9, Sep. 2016, doi: 10.1007/s11940-016-0424-3.

[57]

C. J. D. Hardy et al., 'Hearing and dementia', Journal of Neurology, vol. 263, no. 11, pp. 2339–2354, Nov. 2016, doi: 10.1007/s00415-016-8208-y.

[58]

G. Livingston et al., 'Dementia prevention, intervention, and care', The Lancet, vol. 390, no. 10113, pp. 2673–2734, Dec. 2017, doi: 10.1016/S0140-6736(17)31363-6.

[59]

J. C. Goll, S. J. Crutch, and J. D. Warren, 'Central auditory disorders: toward a neuropsychology of auditory objects', Current Opinion in Neurology, vol. 23, no. 6, pp. 617–627, Dec. 2010, doi: 10.1097/WCO.0b013e32834027f6.

[60]

M. Husain, Oxford textbook of cognitive neurology and dementia. [Oxford]: Oxford University Press, 2016 [Online]. Available: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760

[61]

K. Blennow, J. Hardy, and H. Zetterberg, 'The Neuropathology and Neurobiology of Traumatic Brain Injury', Neuron, vol. 76, no. 5, pp. 886–899, Dec. 2012, doi: 10.1016/j.neuron.2012.11.021.

[62]

D. H. Smith, V. E. Johnson, and W. Stewart, 'Chronic neuropathologies of single and repetitive TBI: substrates of dementia?', Nature Reviews Neurology, vol. 9, no. 4, pp. 211–221, Apr. 2013, doi: 10.1038/nrneurol.2013.29.

[63]

A. C. McKee et al., 'The spectrum of disease in chronic traumatic encephalopathy', *Brain*, vol. 136, no. 1, pp. 43–64, Jan. 2013, doi: 10.1093/brain/aws307.

[64]

S. Fleminger, 'Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 74, no. 7, pp. 857–862, Jul. 2003, doi: 10.1136/jnnp.74.7.857.

[65]

G. Scott et al., 'Amyloid pathology and axonal injury after brain trauma', *Neurology*, vol. 86, no. 9, pp. 821–828, Mar. 2016, doi: 10.1212/WNL.0000000000002413.

[66]

'Hereditary and sporadic beta-amyloidoses'. [Online]. Available: <https://www.bioscience.org/2013/v18/af/4173/fulltext.htm>

[67]

G. V. W. Johnson, 'Tau phosphorylation in neuronal cell function and dysfunction', *Journal of Cell Science*, vol. 117, no. 24, pp. 5721–5729, Nov. 2004, doi: 10.1242/jcs.01558.

[68]

T. Revesz et al., 'Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies', *Acta Neuropathologica*, vol. 118, no. 1, pp. 115–130, Jul. 2009, doi: 10.1007/s00401-009-0501-8.

[69]

T. J. Montine et al., 'National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach', *Acta Neuropathologica*, vol. 123, no. 1, pp. 1–11, Jan. 2012, doi: 10.1007/s00401-011-0910-3.

[70]

D. R. Thal, 'Neurodegeneration in Normal Brain Aging and Disease', *Science of Aging Knowledge Environment*, vol. 2004, no. 23, pp. pe26–pe26, Jun. 2004, doi: 10.1126/sageke.2004.23.pe26.

[71]

H. Braak and E. Braak, 'Staging of alzheimer's disease-related neurofibrillary changes', *Neurobiology of Aging*, vol. 16, no. 3, pp. 271–278, May 1995, doi: 10.1016/0197-4580(95)00021-6.

[72]

S. S. Mirra et al., 'The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease', *Neurology*, vol. 41, no. 4, pp. 479–479, Apr. 1991, doi: 10.1212/WNL.41.4.479.

[73]

T. J. Montine et al., 'National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach', *Acta Neuropathologica*, vol. 123, no. 1, pp. 1–11, Jan. 2012, doi: 10.1007/s00401-011-0910-3.

[74]

R. Dobson and D. Alvares, 'The difficulties with vitamin B', *Practical Neurology*, vol. 16, no. 4, pp. 308–311, Aug. 2016, doi: 10.1136/practneurol-2015-001344.

[75]

Jonathan Carr, 'Neurosyphilis', *Practical Neurology*, vol. 3, pp. 328–341, Dec. 2003 [Online]. Available: <https://pn.bmj.com/content/3/6/328>

[76]

F. Graus et al., 'A clinical approach to diagnosis of autoimmune encephalitis', *The Lancet Neurology*, vol. 15, no. 4, pp. 391–404, Apr. 2016, doi: 10.1016/S1474-4422(15)00401-9.

[77]

C. Salvarani, R. D. Brown, and G. G. Hunder, 'Adult primary central nervous system vasculitis', *The Lancet*, vol. 380, no. 9843, pp. 767–777, Aug. 2012, doi: 10.1016/S0140-6736(12)60069-5.

[78]

J. J. Halperin, R. Kurlan, J. M. Schwalb, M. D. Cusimano, G. Gronseth, and D. Gloss, 'Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response', *Neurology*, vol. 85, no. 23, pp. 2063–2071, Dec. 2015, doi: 10.1212/WNL.0000000000002193.

[79]

Arash Asher, 'The effect of cancer treatment on cognitive function.', undefined [Online]. Available: <https://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be>

[80]

F. Graus et al., 'A clinical approach to diagnosis of autoimmune encephalitis', *The Lancet Neurology*, vol. 15, no. 4, pp. 391–404, Apr. 2016, doi: 10.1016/S1474-4422(15)00401-9.

[81]

'Cognitive Impairment Associated with Cancer: A Brief Review', *Innovations in Clinical Neuroscience*, vol. 15, no. 1–2, 2018 [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/>

[82]

L. J. Haddow, J. D. Cartledge, and H. Manji, 'HIV and the brain: from AIDS to old age',

Clinical Medicine, vol. 13, no. Suppl_6, pp. s24–s28, Dec. 2013, doi:
10.7861/clinmedicine.13-6-s24.

[83]

S. Nightingale, B. D. Michael, S. Defres, L. A. Benjamin, and T. Solomon, 'Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed', *Practical Neurology*, vol. 13, no. 6, pp. 354–356, Dec. 2013, doi: 10.1136/practneurol-2013-000689.

[84]

'HIV in the United Kingdom 2016 infographic'. [Online]. Available:
<https://www.gov.uk/government/publications/hiv-in-the-united-kingdom>

[85]

R. F. Itzhaki et al., 'Microbes and Alzheimer's Disease', *Journal of Alzheimer's Disease*, vol. 51, no. 4, pp. 979–984, Apr. 2016, doi: 10.3233/JAD-160152.

[86]

S. Nightingale et al., 'Controversies in HIV-associated neurocognitive disorders', *The Lancet Neurology*, vol. 13, no. 11, pp. 1139–1151, Nov. 2014, doi: 10.1016/S1474-4422(14)70137-1.

[87]

Richard W. Price and Bruce J. Brew, 'The AIDS Dementia Complex', *The Journal of Infectious Diseases*, vol. 158, no. 5, 1988 [Online]. Available:
https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents

[88]

'UK National Guidelines for HIV Testing 2008'. [Online]. Available:
<https://www.bhiva.org/HIV-testing-guidelines>

[89]

L. Zhou, M. Miranda-Saksena, and N. K. Saksena, 'Viruses and neurodegeneration', *Virology Journal*, vol. 10, no. 1, 2013, doi: 10.1186/1743-422X-10-172.

[90]

G. De Chiara et al., 'Infectious Agents and Neurodegeneration', *Molecular Neurobiology*, vol. 46, no. 3, pp. 614–638, Dec. 2012, doi: 10.1007/s12035-012-8320-7.

[91]

K. A. Wendorf et al., 'Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated', *Clinical Infectious Diseases*, vol. 65, no. 2, pp. 226–232, Jul. 2017, doi: 10.1093/cid/cix302.

[92]

K. G. Ghanem, 'REVIEW: Neurosyphilis: A Historical Perspective and Review', *CNS Neuroscience & Therapeutics*, vol. 16, no. 5, pp. e157–e168, Oct. 2010, doi: 10.1111/j.1755-5949.2010.00183.x.

[93]

O. Somasundaram, 'Neuro syphilis: Portrayals by Sir Arthur Conan Doyle', *Indian Journal of Psychiatry*, vol. 51, no. 3, 2009, doi: 10.4103/0019-5545.55103.

[94]

V. Hachinski et al., 'National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards', *Stroke*, vol. 37, no. 9, pp. 2220–2241, Sep. 2006, doi: 10.1161/01.STR.0000237236.88823.47.

[95]

P. B. Gorelick et al., 'Vascular Contributions to Cognitive Impairment and Dementia', *Stroke*, vol. 42, no. 9, pp. 2672–2713, Sep. 2011, doi: 10.1161/STR.0b013e3182299496.

[96]

'Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales', *The Lancet*, vol. 357, no. 9251, pp. 169–175, Jan. 2001, doi: 10.1016/S0140-6736(00)03589-3.

[97]

D. Leys, H. Hénon, M.-A. Mackowiak-Cordoliani, and F. Pasquier, 'Poststroke dementia', *The Lancet Neurology*, vol. 4, no. 11, pp. 752–759, Nov. 2005, doi: 10.1016/S1474-4422(05)70221-0.

[98]

J. T. O'Brien and A. Thomas, 'Vascular dementia', *The Lancet*, vol. 386, no. 10004, pp. 1698–1706, Oct. 2015, doi: 10.1016/S0140-6736(15)00463-8.